- Home
- CODA vs TLSA Comparison
CODA vs TLSA Comparison
Compare CODA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODA
- TLSA
- Stock Information
- Founded
- CODA 1994
- TLSA 2013
- Country
- CODA United States
- TLSA United Kingdom
- Employees
- CODA N/A
- TLSA N/A
- Industry
- CODA Industrial Machinery/Components
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- CODA Industrials
- TLSA Health Care
- Exchange
- CODA Nasdaq
- TLSA Nasdaq
- Market Cap
- CODA 88.8M
- TLSA 187.0M
- IPO Year
- CODA N/A
- TLSA 2000
- Fundamental
- Price
- CODA $8.38
- TLSA $1.70
- Analyst Decision
- CODA Strong Buy
- TLSA
- Analyst Count
- CODA 1
- TLSA 0
- Target Price
- CODA $11.00
- TLSA N/A
- AVG Volume (30 Days)
- CODA 79.4K
- TLSA 325.5K
- Earning Date
- CODA 09-15-2025
- TLSA 05-06-2025
- Dividend Yield
- CODA N/A
- TLSA N/A
- EPS Growth
- CODA 15.09
- TLSA N/A
- EPS
- CODA 0.30
- TLSA N/A
- Revenue
- CODA $24,347,217.00
- TLSA N/A
- Revenue This Year
- CODA $30.82
- TLSA N/A
- Revenue Next Year
- CODA $20.84
- TLSA N/A
- P/E Ratio
- CODA $27.50
- TLSA N/A
- Revenue Growth
- CODA 29.34
- TLSA N/A
- 52 Week Low
- CODA $5.76
- TLSA $0.63
- 52 Week High
- CODA $9.89
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- CODA 55.98
- TLSA 45.08
- Support Level
- CODA $7.85
- TLSA $1.63
- Resistance Level
- CODA $8.80
- TLSA $1.88
- Average True Range (ATR)
- CODA 0.40
- TLSA 0.15
- MACD
- CODA 0.02
- TLSA -0.01
- Stochastic Oscillator
- CODA 57.98
- TLSA 47.95
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.